This article ignores all of the most recent research around GLP-1 medications. For example, recent research confirms reduction in heart disease for patients taking Ozempic/Wegovy. Mounjaro/Zepbound has been found to reduce sleep apnea. It ignores ALL the research on health benefits derives from significant weight reduction. Finally, it i…
This article ignores all of the most recent research around GLP-1 medications. For example, recent research confirms reduction in heart disease for patients taking Ozempic/Wegovy. Mounjaro/Zepbound has been found to reduce sleep apnea. It ignores ALL the research on health benefits derives from significant weight reduction. Finally, it ignores the most recent research showing no risk of an increase in thyroid cancer. By focusing only on Ozempic, and by implication, diabetes, you are ignoring that these medications are, in fact, FDA approved for the treatment of obesity. Please be fair in cover this issue.
Correct. The thyroid cancer finding was in animals and has not been replicated in humans. Semaglutide does reduce both cardiovascular events and death in patients who have previous cardiovascular disease, although the number of patients you need to treat to prevent one death is rather high (60 or so). Also, no increase in deaths from cancer was observed.
This article ignores all of the most recent research around GLP-1 medications. For example, recent research confirms reduction in heart disease for patients taking Ozempic/Wegovy. Mounjaro/Zepbound has been found to reduce sleep apnea. It ignores ALL the research on health benefits derives from significant weight reduction. Finally, it ignores the most recent research showing no risk of an increase in thyroid cancer. By focusing only on Ozempic, and by implication, diabetes, you are ignoring that these medications are, in fact, FDA approved for the treatment of obesity. Please be fair in cover this issue.
Correct. The thyroid cancer finding was in animals and has not been replicated in humans. Semaglutide does reduce both cardiovascular events and death in patients who have previous cardiovascular disease, although the number of patients you need to treat to prevent one death is rather high (60 or so). Also, no increase in deaths from cancer was observed.